BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Non-current Liabilities
All obligations due after more than one year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 99.4% from a year ago
Total non-current liabilities stood at $2.11M at the end of Q1 FY2026, down 99.4% from a year earlier and down 6.1% from the prior quarter. Over 3 fiscal years it compounded at +42910854.1% a year.
Context
- Total non-current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, down 216.9 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -99.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.24M USD
- Year-over-year change
- -59.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.24M | -59.3% |
| FY2024 | 2024-12-31 | 5.52M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -99.4% is the lowest of 10, against a peer median of -7.4%.
- Total non-current liabilities amounts to 0.5% of total assets for BBOT, versus a peer median of 19.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $517.03M USD | -7.4% | +38.4% | 169.5% | |
| Mar 2026 | $327.31M USD | +29.8% | +8.9% | 129.0% | |
| Mar 2026 | $275.24M USD | -20.0% | -3.6% | 83.5% | |
| Sep 2026 | $142.1M USD | -6.5% | -5.8% | 67.9% | |
| Jun 2026 | $139.87M USD | -14.2% | +37.9% | 19.3% | |
| Aug 2026 | $96.25M USD | +41.8% | +14.1% | 8.1% | |
SEPNSepterna, Inc. | Sep 2026 | $86.61M USD | -39.3% | +19.4% | 14.0% |
| Sep 2026 | $28.12M USD | -11.2% | -38.3% | 2.7% | |
| Mar 2026 | CHF 3.47M CHF | +65.9% | -70.5% | 1.4% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $2.11M USD | -99.4% | +42910854.1% | 0.5% |
| Peer median (excluding BBOT) | — | -7.4% | +8.9% | 19.3% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.